BiotechTubeBiotechTube
Home/Pipeline/MGC026

MGC026

Multiple Solid Tumors

Phase 1Active

Key Facts

Indication
Multiple Solid Tumors
Phase
Phase 1
Status
Active
Company
MacroGenics

About MacroGenics

MacroGenics is a fully-integrated biopharmaceutical company with a mission to develop life-changing medicines for patients with cancer. The company has built a broad pipeline of investigational product candidates, including its lead bispecific DART® molecule lorigerlimab, and has established strategic collaborations with global pharmaceutical companies. With in-house GMP manufacturing capabilities and a focus on innovative antibody engineering, MacroGenics aims to address significant unmet needs in oncology.

View full company profile

Therapeutic Areas

OncologyAutoimmune (via partnered TZIELD)

Other Multiple Solid Tumors Drugs

DrugCompanyPhase
BAY 1817080BayerPhase 1
Zanzalintinib + nivolumabExelixisPhase 1b/2
Zanzalintinib + atezolizumabExelixisPhase 1b/2
XL309ExelixisPhase 1
XB010ExelixisPhase 1
XB628ExelixisPhase 1
XB371ExelixisPhase 1
ADU-1805ExelixisPhase 1
Multiple Preclinical ProgramsPerspective TherapeuticsPreclinical
Pre-Targeting PlatformPerspective TherapeuticsPreclinical
VDC PlatformAura BiosciencesPre-clinical/Discovery
MGC028MacroGenicsPhase 1